Nonacog beta pegol

Drug Profile

Nonacog beta pegol

Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009; Refixia

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia B

Most Recent Events

  • 24 Mar 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of Nonacog beta pegol for Haemophilia B (Treatment, Prevention, In adolescents, In children) in European Union
  • 07 Mar 2017 Novo Nordisk initiates enrolment in the phase I paradigm™7 trial for Haemophilia B in Germany (IV) (NCT03075670)
  • 09 Feb 2017 Novo Nordisk has patent protection for Nonacog beta pegol (Novo Nordisk form 20-F, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top